After the GEMINI-ACS-1 trial

---

Atıf İçin Kopyala

YILMAZ M. B.

TURK KARDIYOLOJI DERNEGI ARSIVI-ARCHIVES OF THE TURKISH SOCIETY OF CARDIOLOGY, cilt.45, ss.8-9, 2017 (ESCI)

• Yayın Türü: Makale / Tam Makale
• Cilt numarası: 45
• Basım Tarihi: 2017
• Doi Numarası: 10.5543/tkda.2017.52358
• Dergi Adı: TURK KARDIYOLOJI DERNEGI ARSIVI-ARCHIVES OF THE TURKISH SOCIETY OF CARDIOLOGY
• Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), Scopus, TR DİZİN (ULAKBİM)
• Sayfa Sayıları: ss.8-9
• Sivas Cumhuriyet Üniversitesi Adresli: Evet

Özet

The GEMINI-ACS-1 trial has recently been published. It was designed to test whether low dose rivaroxaban as an antithrombotic agent is as safe as aspirin in patients with acute coronary syndromes (ACS). The trial is important to set light to future of ACS management.